Positive results from SCALE phase III trials for Saxenda (liraglutide) in obesity- Novo Nordisk

Pooled post-hoc analysis results from the SCALE Obesity and Prediabetes, and SCALE Diabetes trials demonstrated that at 56 weeks, people with obesity or who were overweight with comorbidities and treated with Saxenda (liraglutide), from Novo Nordisk, as an adjunct to a reduced-calorie diet and increased physical activity, had a generally consistent effect on weight loss and certain weight related risk factors across baseline Edmonton Obesity Staging System (EOSS) scores. At 56 weeks, greater weight loss was seen in people with obesity or who were overweight, with or without type 2 diabetes, treated with Saxenda compared to placebo consistently across all baseline EOSS scores.

Additionally, improvements in cardiometabolic risk factors (including HbA1c, systolic blood pressure (SBP) and lipid parameters) and physical function were greater in those treated with Saxenda compared to placebo, again, consistently across all baseline EOSS scores. Saxenda was generally well tolerated and observed side effects were in line with previous liraglutide trials. Across EOSS scores, rates of overall adverse events were similar. Data were presented at the 13th International Congress on Obesity (ICO).

Comment: Key results from all trials in the SCALE clinical development program have been published, with further data expected to be presented and published throughout 2016.